Register entry
CUBIST PHARMACEUTICALS LLC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 59
- Exclusivities
- 3
- Countries
- 0
Exclusivity
Patents and exclusivities
59| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7906489 | DIFICIDfidaxomicin | use | Mar 2027 |
| 7378508 | DIFICIDfidaxomicin | substance, product | Jul 2027 |
| 7863249 | DIFICIDfidaxomicin | substance, product | Jul 2027 |
| 8859510 | DIFICIDfidaxomicin | use | Jul 2027 |
| 7906489*PED | DIFICIDfidaxomicin | use | Sept 2027 |
| 7378508*PED | DIFICIDfidaxomicin | use | Jan 2028 |
| 7863249*PED | DIFICIDfidaxomicin | use | Jan 2028 |
| 8859510*PED | DIFICIDfidaxomicin | use | Jan 2028 |
| 8420676 | SIVEXTROtedizolid phosphate | substance, product | Feb 2028 |
| 7129232 | ZERBAXAceftolozane sulfate; tazobactam sodium | substance, product | May 2028 |
| 7816379 | SIVEXTROtedizolid phosphate | substance, product | Jun 2028 |
| 8003673 | CUBICINdaptomycin | use | Sept 2028 |
| 7129232*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Nov 2028 |
| 10065947 | SIVEXTROtedizolid phosphate | product | Feb 2030 |
| 10442829 | SIVEXTROtedizolid phosphate | substance | Feb 2030 |
| 9624250 | SIVEXTROtedizolid phosphate | substance, product | Feb 2030 |
| 9988406 | SIVEXTROtedizolid phosphate | product | Feb 2030 |
| 8946262 | ENTEREGalvimopan | use | Feb 2030 |
| 9138456 | CUBICIN RFdaptomycin | product | Nov 2030 |
| 8426389 | SIVEXTROtedizolid phosphate | substance, product | Dec 2030 |
| 10028963 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2032 |
| 9724353 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2032 |
| 10028963*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2033 |
| 9724353*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2033 |
| 10420841 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2034 |
| 11278622 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2034 |
| 8968753 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2034 |
| 9320740 | ZERBAXAceftolozane sulfate; tazobactam sodium | product | Mar 2034 |
| 9872906 | ZERBAXAceftolozane sulfate; tazobactam sodium | product | Mar 2034 |
| 8906898 | ZERBAXAceftolozane sulfate; tazobactam sodium | substance, product | May 2034 |
| 9808530 | DIFICIDfidaxomicin | product | May 2034 |
| 10376496 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 10933053 | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 10420841*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 11278622*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 8968753*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 9320740*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 9872906*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Sept 2034 |
| 8906898*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Nov 2034 |
| 9808530*PED | DIFICIDfidaxomicin | use | Nov 2034 |
| 10376496*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2035 |
| 10933053*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Mar 2035 |
| 10125149 | ZERBAXAceftolozane sulfate; tazobactam sodium | product | Aug 2035 |
| 10125149*PED | ZERBAXAceftolozane sulfate; tazobactam sodium | use | Feb 2036 |
| Product | Exclusivity | Until |
|---|---|---|
| DIFICIDFIDAXOMICIN | ODE-367 Orphan drug | Jan 2027 |
| SIVEXTROTEDIZOLID PHOSPHATE | NPP New patient population | Apr 2028 |
| ZERBAXACEFTOLOZANE SULFATE; TAZOBACTAM SODIUM | PED Paediatric | Nov 2029 |
Enquiry
Common questions
- Is CUBIST PHARMACEUTICALS LLC FDA approved?
- CUBIST PHARMACEUTICALS LLC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.